Why I’d shun Woodford Patient Capital Trust and buy this super investment trust

Harvey Jones can’t understand the appeal of the woeful Woodford Patient Capital Trust (LON: WPCT) when investors could buy this investment trust flyer instead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

You almost have to feel sorry for ace fund manager Neil Woodford, who has changed from being the nation’s investment golden boy to its whipping boy in just a couple of years.

Losing patience

After a blistering debut, his eponymous vehicle Woodford CF Equity Income has trailed its sector horribly, falling 13.4% over the last 12 months and his £650m vehicle Woodford Patient Capital Trust (LSE: WPCT) has done even worse, falling 15.1% over 12 months, against a 5.1% rise on the All Companies sector.

I hold his equity income fund and am staying loyal for now. As markets turn volatile, his focus on dividend-paying stocks could prove its merits, provided he avoids more reputation-crunching disasters such as doorstep lender Provident Financial. However, I also share Edward Sheldon’s concern that it has strayed away from its original intention.

Loss of trust

I never had much time for Woodford Patient Capital Trust, launched in April 2015, which saw the dividend hero stray into uncharted (for him) small-cap territories, presumably hoping his reputation would see him through. Instead, his reputation has been sunk.

In the early, heady days this trust traded at a premium of as much as 4%, but today it is at a deep discount of 9.59% as investors lose heart. It has also changed tack, taking on more risk rather than less. Solid FTSE 100 companies have been ditched, while the limit on unquoted companies has been enlarged from 60% to 80%, as GA Chester points out here.

Almost half of the fund is invested in just six stocks, with its biggest holding Oxford Nanophore making up a whopping 10.1% of the fund (and down 54% over three years). The next five, Prothena, Purplebricks, Benevolent AI, Immunocore A and Proton Partners International are all at the higher end of the risk scale. This would be fine if the trust was shooting out the lights like so many smaller company funds right now, but it isn’t.

Rude heath

If you want to invest in smaller biotechnology and healthcare stocks, I would suggest an investment trust that has a proven long-term track record in this area, the Worldwide Healthcare Trust (LSE: WWH) launched in April 1995.

If you had invested your full allowance in the fund every year since 1999 you would now have a whopping £794,856, according to the Association of Investment Companies. It is up 28.7% over the last three years, Trustnet shows (which looks even more impressive when set against Woodford’s double-digit loss), and 152% over five years.

Global spread

Worldwide Healthcare Trust invests in a diversified portfolio of global pharmaceutical and biotechnology stocks for capital growth. It uses gearing and derivative transactions to enhance returns and mitigate risk, and holds a wider spread of stocks including established names such as Merck & Co (its top holding at just 4% of the portfolio), Novo Nordisk and Bristol-Myers Squibb

Worldwide Healthcare Trust isn’t directly comparable to Woodford’s UK-focused fund, with roughly two-thirds invested in North American equities, and holdings across Europe, emerging markets and Asia Pacific. It is in demand, trading at a slight premium of 0.94. Woodford may have lost his admirers but this fund certainly hasn’t.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Is this FTSE 100 pharma gem now a brilliant bargain?

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Is Warren Buffett losing his touch?

Our writer's noticed that Warren Buffett’s investment vehicle has underperformed the S&P 500 during three of the past four years.…

Read more »

Investing Articles

Non-energy minerals are the top performers in 2025. These small-cap FTSE shares are leading the charge

Mark Hartley examines which sectors are doing well in 2025 and the FTSE shares that investors should consider to benefit…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Buying 10,000 Vodafone shares generates a passive income of…

Vodafone shares have had a rough ride, with dividends slashed in half. But with its turnaround making steady progress, is…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Buying 1,000 Aviva shares generates an income of…

Aviva shares could be primed to thrive in the long run if its takeover of Direct Line is a success,…

Read more »

Investing Articles

At today’s price, buying 1,000 British American Tobacco shares generates a second income of…

Tobacco companies may not be popular, but the British American Tobacco share price is on the rise, along with its…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

The cheapest UK stock in my ISA is…

This UK stock currently trades at a massive discount to the market. Edward Sheldon believes it's mispriced and that there's…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

Buying 750 Phoenix shares generates a passive income of…

Phoenix shares offer one of the largest yields in the FTSE 100, but could dividends grow even larger by 2029?…

Read more »